{"filings":[{"id":583197,"accession_number":"0001040130-26-000010","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2026-05-21T20:40:56+00:00","items":["5.08"],"status":"ready","headline":"PetMed Express sets 2026 Annual Meeting for Aug 11, 2026; shareholder proposal deadline May 31","event_type":"other","confidence":"high","bullets":["2026 Annual Meeting will be held virtually on August 11, 2026.","New deadlines apply because meeting date is more than 30 days from 2025 Annual Meeting.","Deadline for Rule 14a-8 shareholder proposals and proxy access nominations: May 31, 2026.","Deadline for other proposals and director nominations outside Rule 14a-8: also May 31, 2026.","Shareholders must comply with Bylaws and Exchange Act requirements for submissions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100553,"accession_number":"0001040130-26-000002","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PetMed Express stockholders elect 5 directors, back executive pay, ratify auditor at 2026 annual meeting","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Batushansky, Campbell, LaCamp, Mennen, Solivan; for votes 6.9M-7.3M, against 2.9M-3.5M.","Advisory vote on executive compensation approved: 8.53M for, 1.79M against, 82k abstentions.","Ratification of Baker Tilly as independent auditor for FY2026 passed: 14.98M for, 0.45M against, 79k abstentions.","Broker non-votes of 5.1M shares on director elections and say-on-pay (non-routine items).","15.5M shares represented out of 21.4M outstanding; quorum achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116870,"accession_number":"0001040130-25-000112","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K/A","filed_at":"2025-12-29T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"PetMed Express amends 8-K: RSM dismissal effective Dec 19; Baker Tilly appointed","event_type":"other_material","confidence":"high","bullets":["Dismissal of RSM US LLP effective December 19, 2025, after completing interim reviews for June and Sep 2025 quarters.","No adverse opinions, disagreements, or reportable events with RSM during fiscal years ended March 2024 and 2025.","Baker Tilly US, LLP engaged as new auditor for fiscal year ending March 31, 2026, starting with Dec 2025 quarter review.","No consultations with Baker Tilly on accounting matters prior to engagement; letter from RSM filed as Exhibit 16.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116876,"accession_number":"0001040130-25-000097","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-12-09T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"PetMed Express dismisses RSM as auditor, hires Baker Tilly; cites material weaknesses in controls","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed RSM US LLP as independent auditor effective after interim reviews; Baker Tilly US LLP engaged for FY2026.","No disagreements on accounting principles but multiple reportable events: material weaknesses in ITGC, tone at the top, revenue recognition, and restatements.","Material weaknesses include inadequate control environment, ineffective whistleblower process, and prior Audit Committee chair’s failure to report complaints to RSM.","Former audit reports for FY2024 and FY2025 were unqualified; material weaknesses not fully remediated as of filing date.","Company does not expect auditor change to delay filing of Q1 and Q2 FY2026 Form 10-Qs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116875,"accession_number":"0001040130-25-000091","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["1.01","3.03","5.02","8.01","9.01"],"status":"ready","headline":"PetMed Express extends shareholder rights plan to December 2026","event_type":"other_material","confidence":"high","bullets":["Rights plan expiration extended from December 2, 2025 to December 2, 2026.","Board states shares do not reflect intrinsic value; recent accumulation by certain shareholders.","Plan designed to ensure fair treatment and prevent inadequate takeover bids.","Interim CFO Douglas Krulik salary increased to $330K; new change-of-control severance agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116874,"accession_number":"0001040130-25-000086","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"PetMed Express warns Q2 net sales down ~25% YoY; receives Nasdaq delisting notice","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 net sales estimated at $43.4M-$44.5M vs $58.0M (restated) prior year.","Six-month net sales estimated at $94.5M-$95.6M vs $124.3M (restated) prior year.","Cannot estimate operating income due to pending goodwill impairment analysis.","Cash $36.1M, no debt as of September 30, 2025.","Nasdaq non-compliance for late Q1 and Q2 10-Qs; compliance plan update due by Nov 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":95544000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116873,"accession_number":"0001040130-25-000077","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints James LaCamp to board and audit committee chair; formalizes interim CEO terms","event_type":"leadership","confidence":"high","bullets":["James LaCamp, former Deloitte partner and current CFO of Skydio, appointed to board effective Oct 19, 2025.","LaCamp will serve as Audit Committee Chair beginning Oct 30, 2025; qualifies as audit committee financial expert.","Interim CEO Leslie Campbell entered employment agreement with $1.3M annual salary, at-will, one-year term through Aug 10, 2026.","Board now comprises six directors, five independent; four new directors added since fiscal 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116872,"accession_number":"0001040130-25-000074","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express FY2025 net sales $227M, net loss $6.3M; Q1/Q2 filings delayed","event_type":"earnings","confidence":"high","bullets":["Net sales of $227.0M for FY2025 below preliminary range of $231.6M-$233.6M due to restatement of promotional sales reimbursements to cost of sales.","Net loss of $6.3M widened from preliminary estimated loss of $4.5M-$5.0M, driven by a $1.2M non-cash impairment charge for intangible assets.","Cash balance of $54.7M and no debt as of March 31, 2025.","Company filed Form 10-K; plans to file Q1 and Q2 2025 reports and resume normal quarterly earnings call cadence."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":95544000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116871,"accession_number":"0001040130-25-000064","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["2.06","4.02","8.01"],"status":"ready","headline":"PetMed Express to restate FY2024, FY2023; investigation reveals revenue errors, former CEO/CFO out","event_type":"other_material","confidence":"high","bullets":["Net sales overstated by ~$7.0M in FY2024 and ~$9.0M in FY2023 due to vendor payment misclassification; no net income impact.","Investigation found Dec and Mar accelerated shipments: $133k and $1.1M revenue in wrong periods; $50 coupon and nepotism issues.","Former CEO Sandra Campos, former CFO Robyn D'Elia, former Audit Chair Diana Purcel resigned; Board adopted remediation plan.","Company expects to file FY2025 10-K by mid-October 2025; material weaknesses in internal controls to be reported.","Also recorded $1.2M non-cash impairment of PCRX trade name; possible additional goodwill impairment due to stock decline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133321,"accession_number":"0001040130-25-000059","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"PetMed Express sets interim CEO salary at $550k, awards restricted shares to CFO","event_type":"leadership","confidence":"high","bullets":["Leslie C.G. Campbell, Interim CEO since Aug 11, 2025, receives $550,000 annual base salary.","Douglas Krulik (Chief Accounting Officer) granted 10,000 restricted shares, vesting in 6 months.","Campbell's salary is effective until a formal employment agreement is signed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133320,"accession_number":"0001040130-25-000051","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"PetMed Express receives Nasdaq non-compliance notice; plan due Sept 1, 2025","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified PetMed for late filing of FY2025 10-K and Q1 FY2026 10-Q, violating Listing Rule 5250(c)(1).","Company must submit compliance plan by September 1, 2025; Nasdaq may grant exception until December 29, 2025.","Notice does not immediately affect listing of PETS common stock on Nasdaq.","Company states it is working diligently to complete and file the overdue reports."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133319,"accession_number":"0001040130-25-000049","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"PetMed CEO and CFO resign effective immediately; interim leaders appointed; audit investigation ongoing","event_type":"leadership","confidence":"high","bullets":["CEO Sandra Campos and CFO Robyn D'Elia resigned Aug 11, 2025; severance includes 13-month salary continuation and accelerated RSU vesting.","Board Chair Leslie Campbell named Interim CEO; CAO Doug Krulik named Interim Principal Financial Officer.","Audit Committee investigation into revenue recognition timing and coupon promotion KPIs is ongoing; no completion timeline provided.","Board reduced from 6 to 5 directors; search for permanent CEO and CFO initiated.","Campbell steps down from Audit and Compensation committees; Mennen becomes Lead Independent Director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133318,"accession_number":"0001040130-25-000043","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Diana Garvis Purcel resigns from PetMed Board; board size reduced to six","event_type":"leadership","confidence":"high","bullets":["Diana Garvis Purcel resigned effective July 24, 2025 as Board member and Audit Committee Chair.","Purcel stated no disagreement with company operating policies or practices.","Board reduced size from 7 to 6 directors effective immediately upon resignation.","Leslie C.G. Campbell appointed to fill Audit Committee role and as Chair of Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133317,"accession_number":"0001040130-25-000040","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"PetMed Express receives Nasdaq deficiency notice for late FY2025 10-K filing","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 2, 2025 for non-compliance with Listing Rule 5250(c)(1) due to delayed annual report.","Must submit compliance plan by September 1, 2025; Nasdaq may grant exception until December 29, 2025.","Notice has no immediate effect on trading; company previously filed a Form 12b-25 on June 16, 2025.","Company is working to complete financial statements and file Form 10-K as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133316,"accession_number":"0001040130-25-000036","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"PetMed Express delays FY2025 10-K; Audit Committee probes whistleblower reports on revenue recognition","event_type":"regulatory","confidence":"high","bullets":["10-K filing delayed beyond July 1 extension; Audit Committee investigating anonymous whistleblower reports.","Reports focus on timing of revenue recognition for Q4 autoship orders and a $50 coupon promotion's effect on new customer KPIs.","Investigation ongoing with external legal counsel; no conclusions yet; company does not expect material impact on preliminary results.","Company working to file 10-K as soon as practicable; no definitive timeline provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149975,"accession_number":"0001040130-25-000034","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"PetMed Express prelim Q4 sales $51-53M vs $66.5M; net loss widens to $10M; delays 10-K","event_type":"earnings","confidence":"high","bullets":["Q4 net sales estimated $51.1-53.1M (down ~21% YoY); net loss $9.9-10.4M vs $5.0M prior year.","FY2025 net sales $231.6-233.6M (down ~17% YoY); FY net loss $4.5-5.0M vs $7.5M prior year.","FY net loss includes $8.7M non-cash benefit from executive departure and $6.4M deferred tax asset valuation allowance.","Cash position $54.7M with no debt as of March 31, 2025.","Company filed Form 12b-25; expects to file annual 10-K by July 1, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149974,"accession_number":"0001040130-25-000016","cik":1040130,"company_name":"PETMED EXPRESS INC","ticker":"PETS","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"PetMed Express appoints Peter Batushansky to Board; Dr. Fulgoni to retire at 2025 annual meeting","event_type":"leadership","confidence":"high","bullets":["Peter Batushansky, former CEO of Allivet and current partner at L2 Capital Partners, joins board effective April 9, 2025.","Batushansky will serve on Audit Committee and Corporate Governance and Nominating Committee; board expands from 6 to 7 members.","Dr. Gian Fulgoni, longtime board member and former Chairman, will retire when his term expires at the 2025 annual shareholders' meeting.","This is the third independent director added since 2024; company highlights ongoing board refreshment and transformation strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}